A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources
A multicenter study, including EATRIS Finland institutes from University of Turku (Department of Biochemistry/Biotechnology and Turku Center for Disease Modeling), have developed a Nanoparticle-Lectin Immunoassay based on Serum CA125MGL measurement. They found out that it was better in discriminating patients with epithelial ovarian cancer (EOC) from endometriosis compared to conventional immunoassay. This method could also help to earlier detect the EOC progression. The novel technical concept employing lectins immobilized on fluorescent nano-particles is expected to be universally applicable to glycated cancer biomarkers in general.